BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22899582)

  • 41. Lenalidomide plus rituximab (R
    Becnel MR; Nastoupil LJ; Samaniego F; Davis RE; You MJ; Green M; Hagemeister FB; Fanale MA; Fayad LE; Westin JR; Wang M; Oki Y; Forbes SG; Feng L; Neelapu SS; Fowler NH
    Br J Haematol; 2019 Jun; 185(5):874-882. PubMed ID: 30919940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
    J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type.
    Hoffmann M; Kletter K; Diemling M; Becherer A; Pfeffel F; Petkov V; Chott A; Raderer M
    Ann Oncol; 1999 Oct; 10(10):1185-9. PubMed ID: 10586335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.
    Kiesewetter B; Ferreri AJ; Raderer M
    Oncologist; 2015 Aug; 20(8):915-25. PubMed ID: 26156327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.
    Okamura I; Imai H; Mori K; Ogura K; Isoda A; Mihara K; Matsumoto M; Saito R; Takahashi T; Ikeda T
    Int J Hematol; 2015 Jan; 101(1):46-51. PubMed ID: 25378228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
    Dueck G; Chua N; Prasad A; Finch D; Stewart D; White D; van der Jagt R; Johnston J; Belch A; Reiman T
    Cancer; 2010 Oct; 116(19):4541-8. PubMed ID: 20572046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
    Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K
    Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
    Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?
    Raderer M; Chott A; Drach J; Montalban C; Dragosics B; Jäger U; Püspök A; Osterreicher C; Zielinski CC
    Ann Oncol; 2002 Jul; 13(7):1094-8. PubMed ID: 12176789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.
    Tsang RW; Gospodarowicz MK; Pintilie M; Wells W; Hodgson DC; Sun A; Crump M; Patterson BJ
    J Clin Oncol; 2003 Nov; 21(22):4157-64. PubMed ID: 14615444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).
    Kiesewetter B; Raderer M
    Hematol Oncol; 2020 Oct; 38(4):417-424. PubMed ID: 32469432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lenalidomide after stem-cell transplantation for multiple myeloma.
    McCarthy PL; Owzar K; Hofmeister CC; Hurd DD; Hassoun H; Richardson PG; Giralt S; Stadtmauer EA; Weisdorf DJ; Vij R; Moreb JS; Callander NS; Van Besien K; Gentile T; Isola L; Maziarz RT; Gabriel DA; Bashey A; Landau H; Martin T; Qazilbash MH; Levitan D; McClune B; Schlossman R; Hars V; Postiglione J; Jiang C; Bennett E; Barry S; Bressler L; Kelly M; Seiler M; Rosenbaum C; Hari P; Pasquini MC; Horowitz MM; Shea TC; Devine SM; Anderson KC; Linker C
    N Engl J Med; 2012 May; 366(19):1770-81. PubMed ID: 22571201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subcutaneous dissemination pattern in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma.
    Jonak C; Troch M; Kiesewetter B; Lukas J; Müllauer L; Jäger U; Chott A; Raderer M
    Haematologica; 2012 May; 97(5):766-70. PubMed ID: 22180423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
    Conconi A; Martinelli G; Lopez-Guillermo A; Zinzani PL; Ferreri AJM; Rigacci L; Devizzi L; Vitolo U; Luminari S; Cavalli F; Zucca E
    Ann Oncol; 2011 Mar; 22(3):689-695. PubMed ID: 20810546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
    Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
    Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience.
    Raderer M; Wöhrer S; Streubel B; Troch M; Turetschek K; Jäger U; Skrabs C; Gaiger A; Drach J; Puespoek A; Formanek M; Hoffmann M; Hauff W; Chott A
    J Clin Oncol; 2006 Jul; 24(19):3136-41. PubMed ID: 16769982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement.
    Kuo SH; Cheng AL; Lin CW; Hsu CH; Wu MS; Yeh KH; Tzeng YS; Chen LT
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1387-95. PubMed ID: 21465313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lacrimal gland extranodal marginal zone B-cell lymphoma of MALT-type.
    Kao SC; Kau HC; Tsai CC; Tsay SH; Yang CF; Wu JS; Hsu WM
    Am J Ophthalmol; 2007 Feb; 143(2):311-316. PubMed ID: 17184716
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically.
    Lévy M; Hammel P; Lamarque D; Marty O; Chaumette MT; Haioun C; Blazquez M; Delchier JC
    Gastrointest Endosc; 1997 Oct; 46(4):328-33. PubMed ID: 9351036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.